As mentioned above, CD8+ T cell proliferation can be expected in the lungs of COVID-19 patients, and a significantly higher (89%) average MYC expression was indeed found in the active infection group compared with the control in this data set (P < 0.0032, unpaired Wilcoxon test), supporting SiPSiC's higher robustness. This evidence concerns the gene MYC and COVID-19.